Outcomes of a Comprehensive Mobile Smoking Cessation Program With Nicotine Replacement Therapy in Adult Smokers: Pilot Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

This study aimed to compare engagement, retention, attitudes toward quitting smoking, smoking behavior, and participant feedback between Pivot and QuitGuide, a US Clinical Practice Guideline-based smoking cessation smartphone app from the National Cancer Institute.

Why It Was Studied

Pivot, a US Clinical Practice Guideline-based mobile smoking cessation program, comprises a personal carbon monoxide breath sensor; a smartphone app; in-app, text-based human-provided coaching; nicotine replacement therapy; and a moderated web-based community.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In this remote pilot randomized controlled trial, cigarette smokers in the United States were recruited on the web and randomized to Pivot or QuitGuide.

Participants were offered 12 weeks of free nicotine replacement therapy.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

Outcomes included engagement and retention, attitudes toward quitting smoking, smoking behavior, and participant feedback.

The primary outcome was self-reported app openings at 12 weeks.

Cessation outcomes included self-reported 7- and 30-day point prevalence abstinence (PPA), abstinence from all tobacco products, and continuous abstinence at 12 and 26 weeks.

PPA and continuous abstinence were biovalidated via breath carbon monoxide samples.

What Was Measured

Topics PubMed links to this paper include Smoking Cessation, Smokers, Tobacco Use Cessation Devices, Carbon Monoxide and Pilot Projects.

The authors tagged it with the keywords app, biofeedback, breath sensor, digital health, digital sensor and health promotion.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (JMIR mHealth and uHealth), a journal based in Canada.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.